Trade. re some of the earlier discussion on "placebo " effect.
All these patients are on multiple drugs ...probably steroids now ( note poster Josey's comments ), blood thinners , Dex and whatever else they think may work.
So in a double blinded trial the challenge is to match the patient profile in each arm of the trial. If you have 10 diabetics with kidney disease in one arm ...you need to match with 10 in the other arm ....then try and match the types of drugs each is getting in both arms .
You may also need to match blood types and BMI ( body mass index ) ...as apparently some blood types do better than others and obese patients do the worst . You need to match racial or cultural factors also
So matching these two arms of the trial will be a huge challenge and may explain why we haven't had updates on the IV trial recently.
Once you've matched these populations ...comorbidity's , blood , BMI, drugs they're on etc ...you then add RLF-100 to one arm ( 50% of those in the trial ) and I believe a saline solution to the other .....and compare outcomes .
But the IV is double blinded so know one knows who got the RLF-100 or the saline ...except the DMC ( data monitoring committee )
We know know that on optimal medical therapy ( drugs , prone positioning ) fatality has dropped to around 33% ( would need to chk ) once patient is on a vent.....thats the "placebo " arm .
When we add RLF-100 ...does that drop fatality rates to 10-15% ...or only to 25%
Thats what we need to know .
Unfortunately this IV trial is far more complicated than just giving someone a Statin and the other person a sugar pill ( the placebo ) ...and seeing the affect on LDL cholesterol .
Kiwi
Market Data 
Markets 
AI
